BRPI0413757A - métodos para o tratamento de copd e da hipertensão pulmonar - Google Patents

métodos para o tratamento de copd e da hipertensão pulmonar

Info

Publication number
BRPI0413757A
BRPI0413757A BRPI0413757-4A BRPI0413757A BRPI0413757A BR PI0413757 A BRPI0413757 A BR PI0413757A BR PI0413757 A BRPI0413757 A BR PI0413757A BR PI0413757 A BRPI0413757 A BR PI0413757A
Authority
BR
Brazil
Prior art keywords
methods
pulmonary hypertension
treating copd
copd
treating
Prior art date
Application number
BRPI0413757-4A
Other languages
English (en)
Inventor
Abhya Gupta
Philippe Didier Iacono
Linda Jean Kelash-Cannavo
Jeffreyb Madwed
Jung-Yong Park
Susan Lynn Way
Mehran Yazdanian
Original Assignee
Boehringer Ingelheim Pharma
Boehringer Inglheim France S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Boehringer Inglheim France S A filed Critical Boehringer Ingelheim Pharma
Publication of BRPI0413757A publication Critical patent/BRPI0413757A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS PARA O TRATAMENTO DE COPD E DA HIPERTENSãO PULMONAR". A presente invenção refere-se a métodos para o tratamento da COPD e da hipertensão pulmonar com a utilização de inibidores da quinase MAP p38 em combinação com um ou mais outros ingredientes ativos.
BRPI0413757-4A 2003-08-22 2004-08-19 métodos para o tratamento de copd e da hipertensão pulmonar BRPI0413757A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49737603P 2003-08-22 2003-08-22
PCT/US2004/027013 WO2005018624A2 (en) 2003-08-22 2004-08-19 Methods of treating copd and pulmonary hypertension

Publications (1)

Publication Number Publication Date
BRPI0413757A true BRPI0413757A (pt) 2006-10-31

Family

ID=34216120

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413757-4A BRPI0413757A (pt) 2003-08-22 2004-08-19 métodos para o tratamento de copd e da hipertensão pulmonar

Country Status (11)

Country Link
US (1) US20050148555A1 (pt)
EP (1) EP1658060A2 (pt)
JP (1) JP2007503393A (pt)
CN (1) CN1838958A (pt)
AU (1) AU2004266719A1 (pt)
BR (1) BRPI0413757A (pt)
CA (1) CA2536293A1 (pt)
IL (1) IL173829A0 (pt)
RU (1) RU2006108864A (pt)
WO (1) WO2005018624A2 (pt)
ZA (1) ZA200600411B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4943837B2 (ja) 2003-04-03 2012-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良インヒビター
US20090018092A1 (en) 2004-03-16 2009-01-15 The Regents Of The University Of California Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
WO2006045119A2 (en) * 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
NZ556732A (en) 2005-01-25 2011-11-25 Synta Pharmaceuticals Corp Pyrazine compounds for inflammation and immune-related uses
AU2006224623A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
ITMI20050417A1 (it) * 2005-03-15 2006-09-16 Medestea Res & Production S R L Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica
PT2366393E (pt) 2005-04-19 2013-10-04 Takeda Gmbh Roflumilaste para o tratamento da hipertensão pulmonar
JP2007217322A (ja) * 2006-02-15 2007-08-30 Ube Ind Ltd 慢性閉塞性肺疾患の治療又は予防のための医薬組成物
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
GB0700972D0 (en) * 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
CA2691003A1 (en) * 2007-06-26 2008-12-31 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
CN102333770B (zh) 2008-12-11 2015-01-28 瑞斯比维特有限公司 P38map激酶抑制剂
JPWO2010110314A1 (ja) * 2009-03-27 2012-10-04 協和発酵キリン株式会社 核酸を含有する肺高血圧症治療剤
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
MY167216A (en) * 2011-12-09 2018-08-14 Chiesi Farm Spa Kinase inhibitors
JP2015522528A (ja) * 2012-05-09 2015-08-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 慢性閉塞性肺疾患の予防または治療方法および医薬組成物
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP5934658B2 (ja) * 2013-01-29 2016-06-15 Ｊｘエネルギー株式会社 イミド−ウレア化合物及びその製造方法、グリース用増ちょう剤並びにグリース組成物
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
KR102283883B1 (ko) 2013-04-02 2021-07-29 옥슬러 액퀴지션즈 리미티드 키나제 저해제
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CA2934199A1 (en) 2013-12-20 2015-06-25 Respivert Limited Urea derivatives useful as kinase inhibitors
UA122213C2 (uk) 2014-09-10 2020-10-12 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Сполуки як інгібітори кінази, реаранжованої під час трансфекції (ret)
MX2017003118A (es) 2014-09-10 2018-05-07 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret).
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
WO2017174995A1 (en) 2016-04-06 2017-10-12 Respivert Limited Kinase inhibitors
US10912778B2 (en) * 2016-12-14 2021-02-09 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP2021506978A (ja) 2017-12-22 2021-02-22 ラヴェンナ ファーマシューティカルズ，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112245583B (zh) * 2020-10-14 2022-07-05 浙江大学 呼吸***疾病的治疗产品、诊断产品及研究动物模型

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
KR100709497B1 (ko) * 1999-03-12 2007-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 소염제로서 유용한 화합물 및 이의 제조방법
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
JP2002302458A (ja) * 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 併用薬
WO2002051442A1 (fr) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions
CA2445003A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
CA2453147A1 (en) * 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
US7211575B2 (en) * 2001-09-13 2007-05-01 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
WO2003049742A1 (en) * 2001-12-11 2003-06-19 Boehringer Ingelheim Pharmaceuticals, Inc. Method for administering birb 796 bs
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2004014870A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions

Also Published As

Publication number Publication date
RU2006108864A (ru) 2007-09-27
ZA200600411B (en) 2007-01-31
US20050148555A1 (en) 2005-07-07
CA2536293A1 (en) 2005-03-03
CN1838958A (zh) 2006-09-27
EP1658060A2 (en) 2006-05-24
IL173829A0 (en) 2006-07-05
AU2004266719A1 (en) 2005-03-03
WO2005018624A2 (en) 2005-03-03
JP2007503393A (ja) 2007-02-22
WO2005018624A3 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
BRPI0413757A (pt) métodos para o tratamento de copd e da hipertensão pulmonar
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
DE60025812D1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DE602004024374D1 (de) Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
ATE318812T1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ATE481497T1 (de) Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
ME00275B (me) ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20065762L (no) Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
BRPI0508795A (pt) composição de tratamento capilar, uso da composição, método de tratamento de cabelos e método de fabricação de composição de tratamento capilar
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.